
Testosterone Labeling and the FDA Expert Panel
FDA expert panel members review how TRAVERSE and new evidence prompted testosterone label revisions, and what they mean for treating deficiency.
Welcome back to another Urology Times Webinar series. In this episode, moderator Amy M. Pearlman, MD, urologist and co-founder of Prime Institute is joined by Abraham Morgentaler, MD, FACS; Mohit Khera, MD, MBA, MPH; and Helen L. Bernie, DO, MPH, to open the discussion on testosterone deficiency and the recent FDA label revisions.
Want the whole discussion? Click here
A product label carries far more weight than its regulatory purpose suggests, and for testosterone that weight has long rested on outdated assumptions. Morgentaler explains that the label is a negotiated document between the FDA and manufacturers. Even so, many clinicians outside urology treat it as the authoritative guide to risk and appropriate use. He traces how a cardiovascular warning and a limitation excluding age-related hypogonadism entered the label around 2015. He also shows how prostate cancer language dating back decades reflected fears rooted in Huggins’s early work.
Khera clarifies that the December 2025 meeting was an expert panel rather than an advisory committee, with each speaker assigned a focused topic and rehearsed to fit a tightly timed program. He connects that work, alongside the TRAVERSE trial (NCT03518034), to the FDA’s subsequent request that manufacturers revise labeling on prostate cancer, benign prostatic hyperplasia, and age-related use.
Bernie describes an audience of members of the public, society leaders, and reporters, and a collaborative tone in which the agency appeared genuinely interested in aligning regulation with current evidence. For her, the meeting was about more than one medication, since decades of misconceptions have shaped how physicians prescribe and how men view seeking care for low testosterone. Pearlman frames the discussion for a mixed audience of clinicians and patients, and notes that the full panel remains publicly available for viewing.
The takeaway for clinicians is that the proposed revisions represent a long-awaited correction, bringing the label closer to the evidence and to the guidance that professional societies have offered for years.
In the next episode, ‘Testosterone Screening and Cardiovascular Safety in TRAVERSE,’ panelists will continue their discussion on testosterone deficiency and highlight the case for routine testosterone screening and what the TRAVERSE trial revealed about cardiovascular safety across formulations.
Related to this article








